Affiliation:
1. Eli Lilly and Co. Ltd., Lilly Research Centre, Windlesham, Surrey, UK,
2. Eli Lilly and Co. Ltd., Lilly Research Centre, Windlesham, Surrey, UK
3. Lilly Corporate Center, Indianapolis, Indiana
Abstract
Amyloid beta (Aβ) peptides are the major constituent of amyloid plaques, one of the hallmark pathologies of Alzheimer's disease. Accurate and precise quantitation of these peptides in biological fluids is a critical component of Alzheimer's disease research. The current most established assay for analysis of Aβ peptides in preclinical research is enzyme-linked immunosorbent assay (ELISA), which, although sensitive and of proven utility, is a multistep, labor-intensive assay that is difficult to automate completely. To overcome these limitations, the authors have developed and optimized simple, sensitive, homogeneous 384-well assays for Aβ1-42 and Aβ1-40 using AlphaScreen™ technology. The assays are capable of detecting Aβ peptides at concentrations <2 pg/mL and, using a final assay volume of 20 µL, routinely generate Z′ values >0.85. The AlphaScreen™ format has the following key advantages: substantially less hands-on time to run, easier to automate, higher throughput, and less expensive to run than the traditional ELISA. The results presented here show that AlphaScreen™ technology permits robust, efficient, and cost-effective quantitation of Aβ peptides. ( Journal of Biomolecular Screening 2008:101-111)
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献